Telix Completes BiPASS Enrollment and Aligns With FDA
MELBOURNE, Australia and INDIANAPOLIS, September 2, 2026 Telix Pharmaceuticals Limited has completed enrollment of 350 patients in its Phase...
Gozellix
Advertisement
Telix Strengthens Radiopharmaceutical Pipeline with Multiple Late-Stage Clinical Milestones
Melbourne, Australia and Indianapolis, Indiana, U.S. | August 20, 2026 Telix Pharmaceuticals reported strong first-half 2026 performance, highlighting continued...
Telix Expands PSMA-PET Imaging in Prostate Cancer Care
MELBOURNE, Australia, and INDIANAPOLIS, May 15, 2026 Telix Pharmaceuticals Limited announced new strategic collaborations with EDAP TMS S.A. and...
Barinthus Bio Reports Positive Phase 1 Data for VTP-1000
Germantown, MD – December 10, 2025 – Barinthus Biotherapeutics announced new results from the Phase 1 AVALON clinical trial...
Telix and Varian Launch Theranostics-EBRT Precision Oncology Collaboration
Melbourne, Australia & Palo Alto, CA – December 10, 2025 – Telix Pharmaceuticals Limited and Varian, a Siemens Healthineers...
Advertisement
